

Chryso Kanthou

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11860157/publications.pdf>

Version: 2024-02-01

37
papers

2,883
citations

304743

22
h-index

377865

34
g-index

38
all docs

38
docs citations

38
times ranked

3559
citing authors

#	ARTICLE	IF	CITATIONS
1	Disrupting tumour blood vessels. <i>Nature Reviews Cancer</i> , 2005, 5, 423-435.	28.4	867
2	The biology of the combretastatins as tumour vascular targeting agents. <i>International Journal of Experimental Pathology</i> , 2002, 83, 21-38.	1.3	292
3	The tumor vascular targeting agent combretastatin A4-phosphate induces reorganization of the actin cytoskeleton and early membrane blebbing in human endothelial cells. <i>Blood</i> , 2002, 99, 2060-2069.	1.4	270
4	Expression of vascular endothelial growth factor receptors in smooth muscle cells. <i>Journal of Cellular Physiology</i> , 2001, 188, 359-368.	4.1	198
5	Microtubule depolymerizing vascular disrupting agents: novel therapeutic agents for oncology and other pathologies. <i>International Journal of Experimental Pathology</i> , 2009, 90, 284-294.	1.3	175
6	The Tubulin-Binding Agent Combretastatin A-4-Phosphate Arrests Endothelial Cells in Mitosis and Induces Mitotic Cell Death. <i>American Journal of Pathology</i> , 2004, 165, 1401-1411.	3.8	125
7	The endothelial cytoskeleton as a target of electroporation-based therapies. <i>Molecular Cancer Therapeutics</i> , 2006, 5, 3145-3152.	4.1	106
8	Blood Vessel Maturation and Response to Vascular-Disrupting Therapy in Single Vascular Endothelial Growth Factor-A Isoform-Producing Tumors. <i>Cancer Research</i> , 2008, 68, 2301-2311.	0.9	92
9	Induction of Vascular SMC Proliferation by Urokinase Indicates a Novel Mechanism of Action in Vasoproliferative Disorders. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1997, 17, 2848-2854.	2.4	76
10	Radiation Effects on the Cytoskeleton of Endothelial Cells and Endothelial Monolayer Permeability. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 69, 1553-1562.	0.8	75
11	Thrombin-induced proliferation and expression of platelet-derived growth factor-A chain gene in human vascular smooth muscle cells. <i>FEBS Letters</i> , 1992, 314, 143-148.	2.8	73
12	Tumour targeting by microtubule-depolymerising vascular disrupting agents. <i>Expert Opinion on Therapeutic Targets</i> , 2007, 11, 1443-1457.	3.4	71
13	Do Anti-Angiogenic VEGF (VEGFxxb) Isoforms Exist? A Cautionary Tale. <i>PLoS ONE</i> , 2012, 7, e35231.	2.5	46
14	Sydnone Cycloaddition Route to Pyrazole-Based Analogs of Combretastatin A4. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 9473-9488.	6.4	44
15	The anticoagulant factor, protein S, is produced by cultured human vascular smooth muscle cells and its expression is up-regulated by thrombin. <i>Blood</i> , 2000, 95, 2008-2014.	1.4	40
16	Evidence for Cultured Human Vascular Smooth Muscle Cell Heterogeneity: Isolation of Clonal Cells and Study of their Growth Characteristics. <i>Thrombosis and Haemostasis</i> , 1996, 75, 854-858.	3.4	38
17	Perioperative use of iloprost in cardiac surgery patients diagnosed with heparin-induced thrombocytopenia-reactive antibodies or with true HIT (HIT-reactive antibodies) <i>TJ ETQ</i> 1 0.784314 rgBT	1.0	34
18	Anti-vascular agent Combretastatin A-4-P modulates Hypoxia Inducible Factor-1 and gene expression. <i>BMC Cancer</i> , 2006, 6, 280.	2.6	33

#	ARTICLE	IF	CITATIONS
19	Vascular effects dominate solid tumor response to treatment with combretastatin A4-phosphate. <i>International Journal of Cancer</i> , 2011, 129, 1979-1989.	5.1	32
20	Involvement of Pertussis toxin-sensitive and -insensitive G proteins in α -thrombin signalling on cultured human vascular smooth muscle cells. <i>Cellular Signalling</i> , 1996, 8, 59-66.	3.6	27
21	Mechanisms of cytotoxicity induced by horseradish peroxidase/indole-3-acetic acid gene therapy. <i>Journal of Cellular Biochemistry</i> , 2002, 87, 221-232.	2.6	27
22	Thrombin Receptor Activating Peptide (TRAP) Stimulates Mitogenesis, c-fos and PDGF-A Gene Expression in Human Vascular Smooth Muscle Cells. <i>Thrombosis and Haemostasis</i> , 1995, 74, 1340-1347.	3.4	25
23	Tumour Cells Expressing Single VEGF Isoforms Display Distinct Growth, Survival and Migration Characteristics. <i>PLoS ONE</i> , 2014, 9, e104015.	2.5	14
24	Rational Design of Cholesterol Derivative for Improved Stability of Paclitaxel Cationic Liposomes. <i>Pharmaceutical Research</i> , 2018, 35, 90.	3.5	14
25	The vascular targeting agent combretastatin A-4-phosphate induces neutrophil recruitment to endothelial cells in vitro. <i>Anticancer Research</i> , 2003, 23, 3199-206.	1.1	13
26	Targeting the vasculature of tumours: combining VEGF pathway inhibitors with radiotherapy. <i>British Journal of Radiology</i> , 2019, 92, 20180405.	2.2	12
27	Cellular Effects and Signalling Pathways Activated by the Anti-Coagulant Factor, Protein S, in Vascular Cells. <i>Advances in Experimental Medicine and Biology</i> , 2000, 476, 155-166.	1.6	12
28	Influence of soluble or matrix-bound isoforms of vascular endothelial growth factor-A on tumor response to vascular-targeted strategies. <i>International Journal of Cancer</i> , 2013, 133, n/a-n/a.	5.1	11
29	Prothrombin cleavage by human vascular smooth muscle cells: A potential alternative pathway to the coagulation cascade. <i>Journal of Cellular Biochemistry</i> , 1995, 59, 514-528.	2.6	8
30	Evaluation of Sydnone-Based Analogues of Combretastatin A4 Phosphate (CA4P) as Vascular Disrupting Agents for Use in Cancer Therapy. <i>ChemMedChem</i> , 2018, 13, 2618-2626.	3.2	7
31	The influence of hypoxia and energy depletion on the response of endothelial cells to the vascular disrupting agent combretastatin A-4-phosphate. <i>Scientific Reports</i> , 2020, 10, 9926.	3.3	7
32	Selective destruction of the tumour vasculature by targeting the endothelial cytoskeleton. <i>Drug Discovery Today: Therapeutic Strategies</i> , 2007, 4, 237-243.	0.5	6
33	Debunking the Myth of the Endogenous Antiangiogenic Vegfxxx Transcripts. <i>Trends in Endocrinology and Metabolism</i> , 2020, 31, 398-409.	7.1	5
34	The protective role of sphingosine-1-phosphate against the action of the vascular disrupting agent combretastatin A-4 3-O-phosphate. <i>Oncotarget</i> , 2017, 8, 95648-95661.	1.8	5
35	Cellular and Molecular Effects of Thrombin in the Vascular System. , 1998, , 263-282.		2
36	Vascular Disrupting Agents in Cancer Therapy. , 2008, , 809-829.		1

#	ARTICLE	IF	CITATIONS
37	Topological Analysis of the Vasculature of Angiopoietin-Expressing Tumours Through Scale-Space Tracing. Communications in Computer and Information Science, 2017, , 285-296.	0.5	0